It is possible that an initial increase of serum Aβ42 may represent a biomarker that correlates with the occurrence of ALF at a preclinical AD phase and is useful for preventive BACE1 inhibitor evaluation. This evidence concerns the gene BACE1 and Alzheimer disease.